Topoisomerase IIα amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: Results of CALGB 8541/150013

Journal of Clinical Oncology

Volumn 27, Issue 21, 2009, Pages 3430-3436

  Harris, Lyndsay N ^a   Broadwater, Gloria ^a   Abu Khalaf, Maysa ^a   Cowan, David ^a   Thor, Ann D ^a   Budman, Daniel ^a   Cirrincione, Constance T ^a   Berry, Donald A ^a   Winer, Eric P ^a   Hudis, Clifford A ^a   Hayes, Daniel F ^a   Friedman, Paula ^a   Ellis, Matthew ^a   Dressler, Lynn ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; FLUOROURACIL; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CHROMOSOME 17; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESPONSE; GENE DELETION; GENE NUMBER; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; BREAST TUMOR; DRUG EFFECT; DRUG INTERACTION; GENE AMPLIFICATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG INTERACTIONS; FLUOROURACIL; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 70249085601     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.4085     Document Type: Article

References (36)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352: 930-942, 1998
2. Buzdar AU, Kau SW, Smith TL, et al: Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12:123-128, 1989
3. Jones S, Savin M, Holmes F, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
4. Slamon D, Eiermann W, Robert N, et al: BCIRG006: 2nd interim analysis phase III randomized trial comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006 (abstr 52)
5. Borg A, Baldetorp B, Ferno M, et al: ErbB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143, 1991
6. van de Vijver MJ, Peters JL, Mooi WJ, et al: Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988
7. Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Can Inst 90: 1346-1360, 1998
8. Paik S, Bryant J, Wolmark N: ErbB-2 Overexpression and response to chemotherapy: NSABP study. Breast Cancer Res Treat 50:3, 1998 (abstr 19)
9. Dressler LG, Berry DA, Broadwater G, et al: Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23:4287-4297, 2005
10. Paik S, Bryant J, Park C, et al: ErbB-2 and response to doxorubicin inpatients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
11. Pritchard K, Shepherd L, O'Malley F, et al: Her 2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006
12. Smith K, Houlbrook S, Greenall M, et al: Topoisomerase II alpha co-amplification with erbB-2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8:933-938, 1993
13. Kim R, Hirabayashi N, Nishiyama M, et al: Expression of MDR1, GST and Topoisomerase II as an indicator of clinical response to Adriamycin. Anticancer Res 11:429-431, 1991
14. Järvinen TA, Tanner M, Rantanen V, et al: Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847, 2000
15. Järvinen TA, Tanner M, Barlund M, et al: Characterization of topoisomerase II alpha amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150, 1999
16. Harris LN, Yang L, Liotcheva V, et al: Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 7:1497-1504, 2001
17. Rowe TC, Chen GL, Hsiang Y, et al: DNA damage by antitumor acridines mediated by mammalian topoisomerase II. Cancer Res 46:2021-2026, 1986
18. DiGiovanna M, Stern D: Activation statespecific monoclonal antibody detects tyrosine phosphorylated p185 neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 55:1946-1955, 1995
19. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211, 1998
20. DiGiovanna M, Carter D, Flynn S, et al: Functional assay for HER2/neu demonstrates active signaling in a minority of HER2/neu overexpressing invasive human breast tumors. Br J Cancer 74:802-806, 1996
21. Thor A, Liu S, Edgerton S, et al: Activation (tyrosine phosphorylation)of Erb B-2(HER2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 18:3230-3239, 2000
22. Harris L, Tang C, Yang C, et al: Induction of chemotherapy sensitivity in MCF-7 breast cancer cells by heregulin. Clin Cancer Res 4:1005-1012, 1998
23. Jacobson K, Thompson A, Browne G, et al: Automation of fluorescence in situ hybridization pretreatment: A comparative study of different sample types. Mol Diagn 5:209-220, 2000
24. Carter S, Eklund A, Kohane I, et al: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcomes in multiple human cancers. Nat Genet 38:1043-1048, 2006
25. Jacobson K, Morrison L, Henderson B, et al: Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 40:19-31, 2004
26. Schwartz R, Schnitt S, Rousseau A, et al: Topoisomerase IIa expression and response to anthracycline-based neoadjuvant chemotherapy: Results from a randomized clinical trial. Mod Pathol 16:195, 2003
27. Knoop A, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Group. J Clin Oncol 23:7483-7490, 2005
28. Tanner M, Isola J, Wiklund T, et al: Topoisomerase IIa gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu amplified breast cancer: Results from the randomized trial SBG 9401. J Clin Oncol 24:2428-2436, 2006
29. Di Leo A, Gancberg D, Larsimont D, et al: HER-2 amplification and topoisomerase II gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate and 5-fluorouracil. Clin Cancer Res 8:1107-1116, 2002
30. Reference deleted
31. Reference deleted
32. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC -> TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:S5, 2005 (suppl 1)
33. Press M, Bernstein L, Sauter G, et al: Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (Herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005 (abstr 1045)
34. O'Malley FP, Chia S, Tu D, et al: Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). Breast Cancer Res Treat 100:S18, 2006 (suppl 1; abstr 38)
35. Bartlett JMS, Munro A, Dunn JA, et al: Chromosome 17 polysomy as a predictor of anthracycline response: Emerging evidence from the UK NEAT adjuvant breast cancer trial. San Antonio Breast Cancer Conference, San Antonio, TX, December 10-14, 2008 (abstr 45)
36. Lezon-Geyda K, Hicks JB, Tuck DP, et al: Genomic rearrangements in breast cancer: Clinical implications. Biol Ther Breast Cancer 8:7-11, 2007